Xeris Pharmaceuticals | XERS - Ebitda


Xeris Pharmaceuticals reported $-20.94M in EBITDA for its fiscal quarter ending in June of 2026.





Ebitda Change Date
Celltrion KRW 25.72B 6.08B Jun/2026
Cspc Pharmaceutical CNY 2.19B 21.88M Dec/2024
Deva Holding AS TRY 882.9M 201.7M Sep/2023
Dianthus Therapeutics USD -61.38M 14.92M Jun/2026
Divis Laboratories Ltd INR 15.66B 3.04B Sep/2026
Eli Lilly USD 9.46B 3.54B Sep/2026
Kangmei Pharma CNY -12.72M 30.02M Mar/2026
Knight Therapeutics CAD 24.45M 3.46M Dec/2025
Laboratorios Farma EUR 34.94M 102.95M Jun/2025
Malin Corporation EUR -1.1M 200K Dec/2024
Medical Developments International AUD 1.78M 3.78M Dec/2024
Nektar Therapeutics USD -38.9M 7.09M Mar/2026
Neuren Pharmaceuticals AUD 11.14M 165.56M Dec/2025
Organigram Holdings CAD 15.45M 20.21M Jun/2026
Pacira USD 50.45M 1.78M Sep/2026
Perrigo USD 156.6M 83M Sep/2026
Pharma Mar EUR 9.63M 8.93M Sep/2026
Qiagen NV USD 219.78M 12.13M Sep/2026
Sartorius EUR 279.9M 600K Sep/2026
Sino Biopharmaceutical CNY 2.59B 1.57B Dec/2024
Supernus Pharmaceuticals USD 55.6M 24M Sep/2026
Tilray USD 8.36M 1.82M Sep/2025
Zealand Pharma A/S -379M 348.47M Mar/2026
Zhangzhou Pientzehuang Pharmaceutical CNY 419.24M 463.46M Jun/2026